PDS Biotechnology Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 42.94 million compared to USD 40.85 million a year ago. Basic loss per share from continuing operations was USD 1.39 compared to USD 1.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 USD | +10.49% |
|
+15.33% | -36.42% |
24/06 | Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer | CI |
12/06 | B. Riley Lowers Price Target on PDS Biotechnology to $9 From $11, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.42% | 12Cr | |
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+25.47% | 2.7TCr | |
-20.05% | 2.04TCr | |
-16.28% | 1.59TCr | |
-15.89% | 1.64TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |
- Stock Market
- Equities
- PDSB Stock
- News PDS Biotechnology Corporation
- PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023